OS data from the PATHWAY trial comparing palbociclib plus tamoxifen versus placebo plus tamoxifen in Asian patients with ABC, though not yet mature, also showed a trend toward prolonged OS in the palbociclib plus tamoxifen arm (HR 0.73; 95% CI 0.442–1.207) [ 18 ].
← all excerpts
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.
1
—
—